Recurrent Falls, Orthostasis, and Polypharmacy After Fracture

Prioritize drugs that plausibly contribute to falls, orthostasis, sedation, and cognitive impairment, while preserving agents with clear ongoing benefit.

• Lorazepam 1 mg nightly: long-acting benzodiazepine in an older adult; causes sedation, impaired balance, nocturnal confusion, and falls. It is the highest-yield deprescribing target, especially with only 3 hours of sleep and nocturia.
• Oxybutynin: strongly anticholinergic; worsens cognition, causes dry mouth, urinary retention, and confusion. Consider stopping or switching to a non-anticholinergic bladder strategy after behavioral measures.
• Amitriptyline 25 mg: anticholinergic and orthostatic; likely contributing to the 24/12 mmHg postural drop and sedation. At this dose it is unlikely to be treating depression effectively.
• Metoprolol and lisinopril: both may contribute to orthostasis and bradycardia. With HR 58, standing BP 84/50, eGFR 38, and K 5.1, reassess whether doses can be reduced; do not simply stop without a plan for BP control.
• Donepezil: can cause bradycardia and syncope; HR 58 warrants review, but do not stop abruptly without discussing goals and diagnosis.
• Aspirin: clarify indication. If primary prevention, the bleeding risk after a fall may outweigh benefit.

Avoid changing everything at once: the goal is to identify the minimum change with the largest safety gain, then reassess orthostatics, cognition, urinary symptoms, and sleep.

Use a stepwise, monitored taper rather than abrupt discontinuation.

1. Stop or reduce the highest-risk sedative first. Reduce lorazepam by roughly 10–25% every 2 weeks, with slower tapering near the end; abrupt withdrawal can cause rebound insomnia, anxiety, and seizures. Offer behavioral sleep measures and treat nocturia contributors.
2. Address anticholinergic burden next. Stop oxybutynin or replace it; if she has urgency, start bladder training, timed voiding, and review caffeine/alcohol. Reassess postvoid residual if retention is suspected.
3. Recheck orthostatic vitals and renal function 1–2 weeks after each cardiovascular change. A standing systolic below 90 or symptoms of presyncope warrants further dose reduction.
4. Taper amitriptyline after the sedative and anticholinergic changes, watching sleep, mood, and neuropathic pain.

Safety plan: home safety evaluation, night light and bedside commode, physical therapy for gait and transfer training, vitamin D and bone health assessment, fracture liaison follow-up, and a clear “who to call” plan. Because she lives alone, involve a daughter or neighbor with permission for medication prompting and check-ins. Document the rationale and give a written taper schedule. Monitor for withdrawal, rebound symptoms, BP/HR, falls, and confusion at each step.

Do not simply say “stop driving” or “keep driving.” Use a risk-based approach.

• Ask about near-misses, getting lost, night driving, and whether others have expressed concern. Six falls in 3 months and orthostasis at 1 minute are meaningful red flags, but they do not automatically establish unfit driving.
• Explain that dizziness on standing, sedating medications, and slowed reaction time increase crash risk. Recommend no driving until orthostasis and sedation are addressed, especially at night and in unfamiliar areas.
• Refer for a formal driving evaluation (occupational therapy or state program) if there is concern about attention, judgment, or processing speed. Arrange a supervised on-road assessment if available.
• Involve a family member with the patient’s permission for observation and transportation planning.
• Document the specific concerns, counseling given, referral, and the patient’s understanding. Follow state reporting requirements, which vary.

The reasoning: driving is an instrumental activity of daily living with public safety implications, but the decision should be individualized and reassessed after deprescribing and orthostasis management rather than made from a single fall count.